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Introduction
Drug product information (PI) provides details on 
the approved clinical use of drugs listed by the 
Therapeutic Goods Administration (TGA) in 
Australia. This includes clinical indication, route of 
administration, dose and population group. 
Information included in PIs is derived from clinical 
trials that support the use of a drug in each of 
these areas. Based on the pharmacology of a drug 
in relation to its approved indication, however, 
treatment of other medical conditions not listed on 
the PI may also be rationalised. Off-label prescribing 
occurs when a drug is prescribed for one or more 
criteria that are not included in the PI and, as such, 
information regarding appropriate dose for the 
condition or population group, pharmacokinetics/
pharmacodynamics, and potential adverse effects 
may not be available in the PI or Consumer 
Medicines Information  (CMI). Nevertheless, off-
label prescribing may be justified by good quality 
evidence from clinical trials or systematic reviews 
of the literature, and a number of examples have 
been accepted in general and specialist clinical 
practice.
For example, until recently misoprostol was only 
approved by the TGA for treatment and prevention 
of upper gastrointestinal (GI) ulceration. It is 
commonly used off-label in obstetrics for treatment 
of post-partum haemorrhage as part of a management 
algorithm since it has demonstrated effective 
haemorrhage prevention and control in combination 
with oxytocin (Tuncalp et al., 2012). Regimes for 
use of misoprostol in gynaecology to evacuate the 
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Abstract
Clinical use of drugs is approved for specified clinical indication, route of administration, dose and population 
group. Off-label prescribing of a registered medicine occurs outside of these parameters and may be justified by 
pharmacology and physiology, as well as sufficient evidence from published clinical trials and reviews.
Misoprostol and mifepristone in combination have recently been registered in Australia for medical termination of 
pregnancy in women of child-bearing age. There is good clinical evidence for efficacy and safety of misoprostol in 
uterine evacuation in both miscarriage and termination of pregnancy. The pharmacological effects of misoprostol 
on the uterus and clinical outcomes in both early miscarriage and abortion are comparable.
Medical management of miscarriage with misoprostol in Australia is performed off-label. A woman presenting 
with first trimester miscarriage must be clearly informed that use of misoprostol in her case is for a non-approved 
indication. This raises the issue of inequity in her management compared with that of first trimester medical 
abortion, including being treated off-label and the potential cost of non-subsidised medication. The clinician must 
also be careful to use an evidence-based protocol that would withstand medicolegal challenge in the case of an 
adverse outcome.
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Registration of mifepristone
Mifepristone was first registered for medical 
abortion in Europe in 1988 and now has registration 
in many countries worldwide. From 1996 to 2005 in 
Australia mifepristone was classified as a  “restricted 
good” which could only be imported with written 
approval of the federal Minister for Health. In 2006 
the Therapeutic Goods Amendment (Repeal of 
Ministerial responsibility for approval of RU486) 
Bill 2005 was passed in Parliament which enabled 
the TGA to assess the efficacy, safety and quality of 
mifepristone should any application for registration 
be made.
No drug sponsor made immediate application for 
registration to the TGA so mifepristone remained 
an unapproved drug in Australia. It was, however, 
available to Authorised Prescribers under provisions 
of the Therapeutic Goods Act 1989 which permitted 
importation and use of drugs recognised and used 
overseas but that were currently unavailable in 
Australia.
In 2012, mifepristone (Therapeutic Goods 
Administration, 2014) was approved for use in 
combination with misoprostol (Therapeutic Goods 
Administration, 2012) for medical abortion in 
women of child-bearing age. Prescription is 
restricted to clinicians who have undertaken defined 
women’s health training administered by the drug 
sponsor, and who have registered on the specific 
prescribing program. Indications for use are 
1. Medical termination of a developing intra- uterine 
pregnancy up to 63 days of gestation, in sequential 
combination with a prostaglandin analogue; and 
2. preparation for the action of registered 
prostaglandin analogues that are indicated for the 
termination of pregnancy for medical reasons 
beyond the first trimester.
Clinical use and guidelines
Combined mifepristone and misoprostol has 
reported widespread use for early first trimester 
abortions and has been the subject of a number of 
reviews (Kulier et al., 2011; Raymond et al., 2013).
The combination has an acceptable safety profile 
in clinical practice (Goldstone et al., 2012; Cleland 
et al.,2013) and controlled administration for 
abortion in outpatient and home settings has also 
been successfully performed even prior to formal 
registration of these drugs in Australia (de Costa 
et al., 2007; Mulligan and Messenger, 2011). 
Nevertheless, significant adverse events including 
incomplete abortion, sepsis and death have all been 
reported (Murray and Wooltorton, 2005; Goldstone 
et al., 2012). The recommendation from the Royal 
contents of a gravid uterus, in both miscarriage and 
abortion have also been described (Gomez Ponce de 
Leon et al., 2007) and evaluated (Dodd and 
Crowther, 2010). Recently, misoprostol has also 
been approved in Australia for use in combination 
with mifepristone to terminate pregnancy in women 
of child-bearing age.
Pharmacology
Misoprostol (15-deoxy-16-hydroxy-16-methyl 
PGE1) is an orally active synthetic prostaglandin 
E1 (PGE1) methyl ester analogue. After oral 
administration, misoprostol rapidly de-esterifies to 
its biologically active form, misoprostolic acid. It 
has four major effects: gastrointestinal cytoprotection 
(approved therapeutic indication), uterotonicity, 
and diarrhoea and abdominal pain which are 
regarded as adverse effects. Cytoprotective effect is 
mainly by topical contact, with inhibition of gastric 
acid secretion and induction of oedema of the 
mucosa and submucosa, increasing the thickness of 
both layers. Uterotonicity requires binding to 
receptors in uterine smooth muscle and are mediated 
systemically after oral dosing. Abdominal pain, 
diarrhoea and flatulence are probably the result of 
exposure to the released misoprostolic acid and 
correlate well with the timing and magnitude of the 
misoprostolic acid peak plasma concentration 
(Davies et al., 2001).
Mifepristone (also known as RU-486) is a 
synthetic antiprogestin steroid with high affinity for 
the glucocorticoid and progesterone receptors and a 
weak affinity for the androgen receptor. Mifepristone 
acts by binding to the human uterine progesterone 
receptor with twice the affinity of that of 
progesterone, thus competitively inhibiting the 
endometrial and myometrial effects effect of 
progesterone. Under some circumstances, in the 
absence of progesterone, mifepristone may also act 
as a progesterone agonist (Robbins and Spitz, 1996). 
Its mechanism of action at the cellular level is highly 
complex and a variety of hypotheses have been 
proposed. During pregnancy mifepristone sensitises 
the myometrium to the contraction inducing action 
of prostaglandins (Swahn and Bygeeman, 1988). 
Administration of mifepristone in early pregnancy 
results in regular uterine contractility and increased 
sensitivity to prostaglandins. Moreover, with high 
concentrations of progesterone, blockage of 
decidual progesterone receptors by mifepristone 
results in withdrawal of progesterone support to the 
endometrium, leading to uterine bleeding and 
disruption of placental function. First trimester 
actions also include reduced cervical resistance, 
dilatation and opening of the cervix.
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This raises a number of issues when dealing with 
women presenting with first trimester miscarriage 
for whom medical management is a preferred 
option. Off-label prescribing requires the clinician 
to inform the woman that her prescription is not for 
an approved indication as listed on the PI/CMI. The 
rationale for treatment with misoprostol should be 
explained with reference to the evidence available 
to reassure her of the safety and applicability of this 
treatment modality (Gazarian et al., 2006). Adverse 
effects and further information from the PI/CMI for 
misoprostol may be discussed, noting that that 
information is specifically applicable to termination 
of pregnancy but being inferred for her situation.
This properly informed woman might then 
question the reason she may incur a non- subsidised 
fee for misoprostol whereas someone seeking a 
termination need not. She may also become hesitant 
to undertake medical management due to this 
personal cost and questions about something called 
“off-label” treatment. Instigation of management 
with misoprostol should commence as soon as 
reasonable given the clinical and emotional 
circumstances surrounding the miscarriage. A delay 
in medical management has been shown to result in 
significantly increased emergency department 
presentations and need for emergency surgical 
management (Torre et al., 2012). She may also 
decide not to undergo medical management at all 
and instead opt for surgical management. The may 
place an increased burden on the healthcare system 
given the lower cost of medical versus surgical 
management in circumstances such as incomplete 
or inevitable miscarriage (Rausch et al., 2012), as 
well as an increased risk of preterm birth in 
subsequent pregnancies (Lemmers et al., 2016). 
Clinicians, too, should be cautious when 
managing first trimester miscarriage with miso-
prostol. Since there are no formal guidelines in 
place, care must be taken when prescribing off-label 
to select a robust protocol that is supported with 
good evidence (Creinin et al., 2006). Public hospitals 
should have in place protocols approved at local and 
district levels, if not by state-wide policy if possible. 
Private clinicians or organisations should also have 
a credible system available that would withstand 
peer-review and legal challenge. Deviation from 
evidence-based regimens may leave the clinician 
and institution open to medicolegal challenge in the 
case of an adverse outcome or event.
The utility of misoprostol is not being questioned 
since it has great applicability in gynaecology in the 
Australian setting (Krishnan et al., 2014). The 
subtleties regarding indicated versus off-label use 
of misoprostol, however, must be given due 
attention given the transparency and evidence- 
Australian and New Zealand College of Obstetricians 
and Gynaecologists (RANZCOG, 2012) is that 
“Medical termination should not be performed in an 
isolated or an inaccessible setting which lacks ready 
access to suitable emergency care (in a service 
accepting this responsibility) from administration of 
mifepristone until termination of pregnancy is 
complete.”
There is still debate as to the appropriate regime 
for medical abortion in using mifepristone and 
misoprostol. According to the PI misoprostol tablets 
are to be administered orally. One large systematic 
review has found better clinical outcomes with 
vaginal versus oral administration, and reduced 
adverse effects for vaginally versus sublingual or 
buccal misoprostol (Kulier et al., 2011). The current 
approved dose of mifepristone is 200 mg in Australia 
whereas a dose of 600 mg of mifepristone is 
approved by the Food and Drug Administration 
(FDA) for use in the USA (Creinin et al., 2006). The 
International Federation of Gynecology and 
Obstetrics (FIGO) guidelines recommend only 
200 mg of mifepristone (Faúndes, 2011) which is 
also supported by recent evidence (Raymond et al., 
2013). It is likely that dosing regimens will continue 
to be researched and further evidence will be 
obtained that will shape recommended dosage, 
frequency and route of administration at different 
gestations.
Off-label use of misoprostol for miscarriage
Medical management of both early (miscarriage) 
and late pregnancy loss may be achieved with 
misoprostol. Its widespread use for management of 
first trimester miscarriage is well-supported by good 
quality evidence worldwide (Gomez Ponce de Leon 
et al., 2007; Neilson et al., 2013). Misoprostol is 
well tolerated and has an acceptable adverse effect 
and safety profile. Unfortunately there is still little 
uniformity in recommended treatment regimens 
although there is increasing evidence that lower 
doses may yield good results both clinically and 
psychologically (Barcelo et al., 2012; Petersen et 
al., 2013).
Misoprostol is clinically effective in management 
of miscarriage, has cost-benefits over other methods, 
and is versatile from the point of view of storage, 
dosing regimen and route of administration. Yet, 
there is a clear disparity between its approved use 
for abortion and its off-label use for management of 
miscarriage. The physiological and pharmacological 
mechanisms involved in both these circumstances 
can be assumed to be directly comparable but for 
the purpose of approved use of misoprostol they are 
viewed differently.
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